Computational studies of acetylcholinesterase complexed with fullerene derivatives: a new insight for Alzheimer disease treatment

References

• Ali, S. S., Hardt, J. I., & Dugan, L. L. (2008). SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: A structure-activity study. Nanomedicine: Nanotechnology, Biology and Medicine, 4, 283–294.10.1016/j.nano.2008.05.003
   PubMed Web of Science ®Google Scholar
• Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. (2001). Electrostatics of nanosystems: Application to microtubules and the ribosome. Proceedings of the National Academy of Sciences USA, 98, 10037–10041.10.1073/pnas.181342398
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J. C., Van Der Spoel, D., & Van Drunen, R. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91, 43–56.10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28, 235–242.10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Birks, J. (2006) Cholinesterase inhibitors for Alzheimer’s disease. The Cochrane Database of Systematic Reviews, 1, CD005593.
   Google Scholar
• Birks J, Grimley, Evans J, Iakovidou V, Tsolaki M, & Holt, F. E. (2009). Rivastigmine for Alzheimer’s disease. The Cochrane Database of Systematic Reviews, 2, CD001191.
   Google Scholar
• Birks, J., & Harvey, R. J. (2006) Donepezil for dementia due to Alzheimer’s disease. The Cochrane Database of Systematic Reviews, 1, CD001190.
   Google Scholar
• Bosi, S., Da Ros, T., Spalluto, G., & Prato, M. (2003). Fullerene derivatives: An attractive tool for biological applications. European Journal of Medicinal Chemistry, 38, 913–923.10.1016/j.ejmech.2003.09.005
   PubMed Web of Science ®Google Scholar
• Burns, A., & Iliffe, S. (2009). Alzheimer’s disease. BMJ, 338, b158. Retrieved from http://www.bmj.com/content/338/bmj.b158.full.print?10.1136/bmj.b158
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98, 10089–10092.10.1063/1.464397
   Web of Science ®Google Scholar
• Dugan, L. L., Gabrielsen, J. K., Yu, S. P., Lin, T.-S., & Choi, D. W. (1996). Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiology of Disease, 3, 129–135.10.1006/nbdi.1996.0013
   PubMed Web of Science ®Google Scholar
• Durdagi, S., Mavromoustakos, T., Chronakis, N., & Papadopoulos, M. G. (2008). Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations. Bioorganic & Medicinal Chemistry, 16, 9957–9974.
   PubMed Web of Science ®Google Scholar
• Durdagi, S., Supuran, C. T., Strom, T. A., Doostdar, N., Kumar, M. K., Barron, A. R., … Papadopoulos, M. G. (2009). In Silico drug screening approach for the design of magic bullets: A successful example with Anti-HIV fullerene derivatized amino acids. Journal of Chemical Information and Modeling, 49, 1139–1143.10.1021/ci900047s
   PubMed Web of Science ®Google Scholar
• Ehrich, M., Van Tassell, R., Li, Y., Zhou, Z., & Kepley, C. L. (2011). Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. Toxicology in Vitro, 25, 301–307.10.1016/j.tiv.2010.09.010
   PubMed Web of Science ®Google Scholar
• Geula, C., & Mesulam, M., M. (1995). Cholinesterases and the pathology of Alzheimer disease. Alzheimer Disease and Associated Disorders, 9, 23–28.10.1097/00002093-199501002-00005
   PubMed Web of Science ®Google Scholar
• Ginsburg, T. (1963). The conjugate gradient method. Numerische Mathematik, 5, 191–200.10.1007/BF01385890
   Google Scholar
• Gonçalves, A. S., França, T. C. C., Caetano, M. S., & Ramalho, T. C. (2014). Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: Reducing the computational cost in hybrid QM/MM methods. Journal of Biomolecular Structure and Dynamics, 32, 301–307. 10.1080/07391102.2013.765361
   PubMed Web of Science ®Google Scholar
• Gonçalves, A. S., França, T. C. C., Figueroa-Villar, J. D., & Pascutti, P. G. (2011). Molecular dynamics simulations and QM/MM studies of the reactivation by 2-PAM of tabun inhibited human acethylcolinesterase. Journal of the Brazilian Chemical Society, 22, 155–165.10.1590/S0103-50532011000100021
   Web of Science ®Google Scholar
• Gonçalves, A. S., França, T. C. C., da Silva, A. W. S., & Figueroa-Villar, J. D. (2006). Molecular dynamics of the interaction of pralidoxime and deazapralidoxime with acetylcholinesterase inhibited by the neurotoxic agent tabun. Journal of the Brazilian Chemical Society, 17, 968–975.10.1590/S0103-50532006000500022
   Web of Science ®Google Scholar
• Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences, 12, 383–388.10.1016/0165-6147(91)90609-V
   PubMed Web of Science ®Google Scholar
• Hassinen, T., & Peräkylä, M. (2001). New energy terms for reduced protein models implemented in an off-lattice force field. Journal of Computational Chemistry, 22, 1229–1242.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18, 1463–1472.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Honig, B., & Nicholls, A. (1995). Classical electrostatics in biology and chemistry. Science, 268, 1144–1149.10.1126/science.7761829
   PubMed Web of Science ®Google Scholar
• Isakovic, A., Markovic, Z., Todorovic-Markovic, B., Nikolic, N., Vranjes-Djuric, S., Mirkovic, M., … Trajkovic, V. (2006). Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. Toxicological Sciences, 91, 173–183.10.1093/toxsci/kfj127
   PubMed Web of Science ®Google Scholar
• Johnston, H. I., Hutchison, G. R., Christensen, F. M., Aschberger, K., & Stone, V. (2010). The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicological Sciences, 114, 162–182.10.1093/toxsci/kfp265
   PubMed Web of Science ®Google Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., … Cheatham, T. E., 3rd. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33, 889–897.10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Koradi, R., Billeter, M., & Wüthrich, K. (1996). MOLMOL: A program for display and analysis of macromolecular structures. Journal of Molecular Graphics, 14, 51–55.10.1016/0263-7855(96)00009-4
   PubMedGoogle Scholar
• Kumari, R., & Kumar, R. (2014). g_mmpbsa – A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54, 1951–1962.10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lindahl, E., Hess, B., & Van Der Spoel, D. (2001). GROMACS 3.0: A package for molecular simulation and trajectory analysis. Journal of Molecular Modeling, 7, 306–317.
   Web of Science ®Google Scholar
• Mashino, T., Nishikawa, D., Takahashi, K., Usui, N., Yamori, T., Seki, M., Endo, T., Mochizuki, M. (2003). Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorganic Medicinal Chemistry Letters, 13, 4395–4397.10.1016/j.bmcl.2003.09.040
   PubMed Web of Science ®Google Scholar
• Mashino, T., Shimotohno, K., Ikegami, N., Nishikawa, D., Okuda, K., Takahashi, K., Nakamura, S., Mochizuki, M. (2005). Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorganic Medicinal Chemistry Letters, 15, 1107–1109.10.1016/j.bmcl.2004.12.030
   PubMed Web of Science ®Google Scholar
• Matos, K. S., da Cunha, E. F. F., Goncalves, A. S., Wilter, A., Kuca, K., França, T. C. C., & Ramalho, T. C. (2012). First principles calculations of thermodynamics and kinetic parameters and molecular dynamics simulations of acetylcholinesterase reactivators: Can mouse data provide new insights into humans? Journal of Biomolecular Structure and Dynamics, 30, 545–558.
   Web of Science ®Google Scholar
• Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19, 1639–1662.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30, 2785–2791.10.1002/jcc.v30:16
   PubMed Web of Science ®Google Scholar
• Morse, P. M., & Feshbach, H. (1953). Asymptotic series; Method of steepest descent. §4.6. In Methods of theoretical physics. Part I (pp. 434–443). New York: McGraw-Hill, 1953.
   Google Scholar
• Mudher, A., & Lovestone, S. (2002). Alzheimer’s disease – Do tauists and baptists finally shake hands? Trends in Neurosciences, 25, 22–26.10.1016/S0166-2236(00)02031-2
   PubMed Web of Science ®Google Scholar
• Nakamura, S., Mashino, T. (2012). Water-soluble Fullerene Derivatives for Drug Discovery. Journal of Nippon Medical School, 79, 248–254.10.1272/jnms.79.248
   PubMed Web of Science ®Google Scholar
• Nishizawa, C., Hashimoto, N., Yokoo, S., Funakoshi-Tago, M., Kasahara, T., Takahashi, K., Nakamura, S., Mashino T. (2009). Pyrrolidinium-type fullerene derivative-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radical Research, 43, 1240–1247.10.3109/10715760903273849
   PubMed Web of Science ®Google Scholar
• Promsri, S., Chuichay, P., Sanghiran, V., Parasuk, V., & Hannongbua, S. (2005). Molecular and electronic properties of HIV-1 protease inhibitor C60 derivatives as studied by the ONIOM method. Journal of Molecular Structure: THEOCHEM, 715, 47–53.10.1016/j.theochem.2004.10.052
   Web of Science ®Google Scholar
• Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer’s Disease. New England Journal of Medicine, 362, 329–344.10.1056/NEJMra0909142
   PubMed Web of Science ®Google Scholar
• Ramalho, T. C., França, T. C. C., Rennó, M. N., Guimarães, A. P., da Cunha, E. F. F., & Kuča, K. (2010). Development of new acetylcholinesterase reactivators: Molecular modeling versus in vitro data. Chemico-Biological Interactions, 185, 73–77.10.1016/j.cbi.2010.02.026
   PubMed Web of Science ®Google Scholar
• Sayes, C. M., Fortner, J. D., Guo, W., Lyon, D. Y., Boyd, A. M., Ausman, K., … Colvin, V. L. (2004). The differential cytotoxicity of water-soluble fullerenes. Nano Letters, 4, 1881–1887.10.1021/nl0489586
   Web of Science ®Google Scholar
• Shih, J. H., & Chen, C. L. (1995). Molecular dynamics simulation of Bisphenol A Polycarbonate. Macromolecules, 28, 4509–4515.10.1021/ma00117a020
   Web of Science ®Google Scholar
• Shoji, M., Takahashi, E., Hatakeyama, Dai, Iwai, Y., Morita, Y., Shirayama, R., … Kuzuhara, T. (2013). Anti-influenza activity of C60 fullerene derivatives. PLoS ONE, 8(6), e66337.10.1371/journal.pone.0066337
   Google Scholar
• da Silva, A. W. S., & Vranken, W. F. (2012). ACPYPE – AnteChamber PYthon Parser interfacE. BMC Research Notes, 5, 367.10.1186/1756-0500-5-367
   PubMedGoogle Scholar
• Stahl, S. M. (2006). The new cholinesterase inhibitors for Alzheimer’s disease, part 2: Illustrating their mechanisms of action. The Journal of Clinical Psychiatry, 61, 813–814.
   Google Scholar
• Troshina, O. A., Troshin, P. A., Peregudov, A. S., Kozlovskiy, V. I., Balzarinid, J., & Lyubovskaya, R. N. (2007). Chlorofullerene C60Cl6: A precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Organic & Biomolecular Chemistry, 5, 2783–2791.
   PubMed Web of Science ®Google Scholar
• Tzoupis, H., Leonis, G., Durdagi, S., Mouchlis, V., Mavromoustakos, T., & Papadopoulos, M. G. (2011). Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson–Boltzmann surface area calculations. Journal of Computer Aided Molecular Design, 25, 959–976.10.1007/s10822-011-9475-4
   PubMed Web of Science ®Google Scholar
• Wang, J., Chen, C., Li, B., Yu, H., Zhao, Y., Sun, J., … Wan, L. (2006). Antioxidative function and biodistribution of [GD@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochemical Pharmacology, 71, 872–881.10.1016/j.bcp.2005.12.001
   PubMed Web of Science ®Google Scholar
• Wang, I. C., Tai, L. A., Lee, D. D., Kanakamma, P. P., Shen, C. K., Luh, T. Y., … Hwang, K. C. (1999). C 60 and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. Journal of Medicinal Chemistry, 42, 4614–4620.10.1021/jm990144s
   PubMed Web of Science ®Google Scholar